Latest Clinical Trials News

InhaleRx has corrected its quarterly report and revealed a $38.5 million funding deal to fast-track clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, aiming for FDA approval.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

SomnoMed reports a robust 19.8% revenue increase in Q2 FY25 and updates its full-year guidance, reflecting strong demand and operational improvements amid ongoing production enhancements.

Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.

InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.

Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.

Island Pharmaceuticals has enrolled all subjects in the Phase 2b arm of its ISLA-101 dengue fever clinical trial, advancing its antiviral drug development with key results expected in 2025.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.